Biotechnology
Everest Medicines Announces Official Acceptance Granted on NEFECON® Supplementary Application by China National Medical Products Administration
SHANGHAI, July 18, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced thatChina's National Medical Products ...
2024-07-18 08:00
2852
ShiraTronics Unveils Data on their Neurostimulation System for Chronic Migraine
MIAMI BEACH, Fla., July 17, 2024 /PRNewswire/ -- ShiraTronics, a trailblazing clinical-stage neurostimulation company, proudly presented findings from its Australian Pilot Study, RELIEV-CM, at the American Society of Pain and Neuroscience (ASPN) Pain Conference. This pioneering study showcases th...
2024-07-16 22:10
2540
Biosyngen's BRG01 enters Phase II clinical trial, a first-in-kind autologous EBV-Specific CAR-T Therapy for Solid Tumors on Recurrent/Metastatic Nasopharyngeal Carcinoma
SINGAPORE, July 16, 2024 /PRNewswire/ -- Biosyngen, a leading biotechnology company focused on the development of innovative cell therapies, recently announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) inChina has approved the initiation of a...
2024-07-16 17:10
2821
Smart Binhai, Glorious Competition! 2024 China Tianjin Binhai New Area Talent Innovation and Entrepreneurship Competition (Overseas Competition) Hong Kong SAR Division Finals to Begin Soon
HONG KONG, July 15, 2024 /PRNewswire/ -- With the surging waves of global innovations, the 2024 China Tianjin Binhai New Area Talent Innovation and Entrepreneurship Competition (Overseas Competition) Hong Kong SAR Division Finals will soon kick off in Hong Kong SAR on 17th July 2024. As the gatew...
2024-07-15 17:43
2365
CPHI & PMEC Shenzhen 2024: Fostering New Opportunities in Asia and China's Greater Bay Area
SHANGHAI, July 15, 2024 /PRNewswire/ -- CPHI & PMEC China 2024 concluded in June with an exceptional turnout of visitors, setting a new attendance record. Notably, the number of international visitors grew to 11,563, and professionals from the end-to-end pharmaceutical supply chain made meaningfu...
2024-07-15 13:59
2350
Everest Medicines Announces Positive Topline Results from Maintenance Period of Etrasimod Phase 3 Clinical Trial Conducted in Asia for the Treatment of Moderately-to-Severely Active Ulcerative Colitis
SHANGHAI, July 15, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced positive topline data results of the ...
2024-07-15 13:44
2535
Basecare Medical (2170. HK) revenue growth exceeds 50% in 2024H1
SUZHOU, China , July 15, 2024 /PRNewswire/ -- Basecare Medical (2170. HK) released an unaudited interim performance forecast onJuly 12th, stating that the company's revenue for the first half of the year was approximatelyRMB 127 million to RMB 138 million, an increase of approximately 49% to 62% ...
2024-07-15 12:17
4416
MGI Tech Launches DNBSEQ-G400RS FluoXpert in the APAC Region at Medlab Asia & Asia Health 2024
BANGKOK, July 12, 2024 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technologies that drive innovation in life science, today launched DNBSEQ-G400RS FluoXpert in the APAC region and opened early access to the platform at Medlab Asia & Asia Health 2024...
2024-07-12 16:57
4146
Sirnaomics Announces Completion of IND-Enabling Studies of Safety and Efficacy for STP125G with NHP Models, Targeting ApoC3 for Treatment of Cardiovascular Diseases
HONG KONG, GERMANTOWN, Md. and SUZHOU, China, July 12, 2024 /PRNewswire/ -- Sirnaomics Ltd.(the "Company", Stock Code: 2257.HK, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, an...
2024-07-12 16:53
5222
CUHK identifies novel gut microbiome biomarkers to facilitate diagnosis of autism spectrum disorders
Pilot clinical study shows modulation of gut microbiome alleviates anxiety symptoms HONG KONG, July 11, 2024 /PRNewswire/ -- A research team from The Chinese University of Hong Kong (CUHK)'s Faculty of Medicine (CU Medicine) has conducted a large cohort study among 1,627 children with and witho...
2024-07-11 18:36
8419
Initiation of cell therapy research and development program for adult T-Cell leukemia / lymphoma (ATLL)
Initiation of cell therapy research and development program for adult T-Cell leukemia / lymphoma (ATLL) TOKYO, July 11, 2024 /PRNewswire/ -- The National Cancer Center (Tokyo, Japan ) and TheUniversity of Pennsylvania (Philadelphia, PA, USA) have licensed patent rights directed to a chimeric...
2024-07-11 14:24
3159
Borsch Med Launches Ikigai Health Campaign with Zeria's Chondro Max
Community Outreach Campaign Champions Healthy Lifestyle for Healthy Joints SINGAPORE, July 11, 2024 /PRNewswire/ -- Borsch Med Pte Ltd (BM), a leading Health and Nutrition company based inSingapore, and operated and managed by professionals in Goh Joo Hin Pte Ltd (GJH), launched the"Enjoy Your Li...
2024-07-11 12:13
2966
Telix Welcomes CMS Proposal to Improve Payment for Specialised Diagnostic Radiopharmaceuticals
MELBOURNE, Australia, July 11, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today welcomes proposed changes announced by the Centers for Medicare & Medicaid Services (CMS) for the Hospital Outpatient Prospective Payment System (OPPS) rule to improve payments ...
2024-07-11 08:21
2476
Eligo Publishes in Nature a Landmark Study That Unlocks Genome Editing of Bacteria in the Gut
PARIS, July 10, 2024 /PRNewswire/ -- For the first time, a team of scientists at Eligo has demonstrated it was possible to genetically modify bacteria with nearly 100% efficiency directly in the gut of animals. This work provides scientists with a novel strategy to better understand how genes fro...
2024-07-10 23:00
2178
3D Artificial Cornea from Stem Cells: Chula Researchers Advance Canine Corneal Wound Treatment
BANGKOK, July 10, 2024 /PRNewswire/ -- Chulalongkorn University's Faculty of Veterinary Science and the Faculty of Engineering have worked together to research and develop a three-dimensional artificial cornea from stem cells that offers a way to treat deep corneal wounds in dogs. The innovation ...
2024-07-10 09:00
3029
MGI Tech Partners with Australian Research Council Training Centre CEAStAR to Lead Innovation in Antimicrobial Resistance Solutions
BRISBANE, Australia, July 8, 2024 /PRNewswire/ -- MGI Australia Pty Ltd, subsidiary of MGI Tech Co., Ltd., a company committed to building core tools and technologies that drive innovation in life science, proudly announces its strategic partnership with TheUniversity of Queensland(UQ) led Centre...
2024-07-08 17:14
2997
Sirnaomics Announces Interim Results for Successful Completion of the Second Cohort of Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Therapeutics
HONG KONG and GERMANTOWN, Md. and SUZHOU, China, July 8, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", together with its subsidiaries, the "Group" or " Sirnaomics"; stock code: 2257), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, to...
2024-07-08 14:30
3198
Olverembatinib Approved for Commercialization in Macau China
ROCKVILLE, Md. and SUZHOU, China, July 8, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first- and best-in-class therapies for hematological malignancies, announced today that its novel BCR-ABL1 tyro...
2024-07-08 08:55
3291
XPOVIO® (selinexor) Approved for New Indication in DLBCL in China, Bringing a New Treatment Option to Patients in the Country
- Following its initial approval for the treatment of relapsed/refractory multiple myeloma (R/R MM), XPOVIO® has now received approval as a monotherapy for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) marking the second approved indication of ...
2024-07-05 21:18
7557
LakeShore Biopharma to Hold an Extraordinary General Meeting on July 25, 2024, Pursuant to Shareholders' Requisition
GAITHERSBURG, Md., July 5, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for in...
2024-07-05 19:00
5695
Week's Top Stories
Most Reposted
iQIYI LAND Yangzhou to Open on February 8, Marking New Chapter in China's Immersive Entertainment Scene
[Picked up by 276 media titles]
2026-01-01 10:00
ACEN completes transition to 100% renewable energy
[Picked up by 274 media titles]
2025-12-29 18:53Vietnam's Newest EDM Destination, APLUS SAIGON, Debuts With Star-Studded Soft Opening Weekends Featuring Dombresky and Argy
[Picked up by 273 media titles]
2025-12-30 20:12
CYFIRMA's 2025 Impact Recap Showcases DeCYFIR, Preemptive External Threat Landscape Management Platform, Delivering Measurable Global Defense Against Emerging Threats
[Picked up by 264 media titles]
2025-12-29 09:00
ChinaAMC launches Depository Receipts of two Chinese flagship ETFs in Thai exchange
[Picked up by 260 media titles]
2025-12-29 14:27Most Read
China Daily Launches "China Bound" -- An English-Language Smart-Tourism Service Platform for International Travelers
2026-01-01 17:04
7511
